Page 22 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation
P. 22
Chapter 1
References
1. NKR cijfers Hodgkin Lymfoom. Utrecht: Integraal Kankercentrum Nederland; 2021. Available from: https://iknl.nl/kankersoorten/hemato-oncologie/nkr-cijfers/hl.
2. Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-2390.
3. Durmaz M et al. Het diffuus grootcellig B-cellymfoom in Nederland, 2014-2016. Landelijk rapport van het hemato-oncologieregeister van de Nederlandse Kankerregistratie. Utrecht: Integraal Kankercentrum Nederland; 2019. Available from: https://www.iknl.nl/getmedia/acf796a4-47f0-4715- bc86-70be4ad5c0da/Hematologische_kankersoorten_landelijk_rapport_iknl_dlbcl_2014_2016. pdf ”.
4. NKR cijfers Diffuus grootcellig B-cellymfoom en varianten. Utrecht: Integraal Kankercentrum Nederland; 2021. Available from: https://iknl.nl/nkr-cijfers?fs%7Cepidemiologie_id=526&fs %7Ctumor_id=400&fs%7Cregio_id=550&fs%7Cperiode_id=564%2C565%2C566%2C5 67%2C568%2C569%2C570%2C571%2C572%2C573%2C574%2C575%2C576%2C577 %2C578%2C579%2C580%2C581%2C582%2C583%2C584%2C585%2C586%2C587%- 2C588%2C589%2C590%2C591%2C592%2C593%2C563%2C562%2C561&fs%7Cgeslacht_ id=644&fs%7Cleeftijdsgroep_id=677&fs%7Cjaren_na_diagnose_id=687&fs%7Ceenheid_id=703 &cs%7Ctype=line&cs%7CxAxis=periode_id&cs%7Cseries=epidemiologie_id&ts%7Crow Dimensions=periode_id&ts%7CcolumnDimensions=&lang%7Clanguage=nl
5. Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381(9880):1817-1826.
6. Vitolo U, Trněný M, Belada D, et al. Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. J Clin Oncol. 2017;35(31):3529-3537.
7. Dührsen U, Müller S, Hertenstein B, et al. PETAL Trial Investigators. Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): A Multicenter, Randomized Phase III Trial. J Clin Oncol. 2018;36(20):2024-2034.
8. Gottlieb JA, Gutterman JU, McCredie KB, Rodriguez V, Frei E 3rd. Chemotherapy of malignant lymphoma with adriamycin. Cancer Res. 1973;33(11):3024-3028.
9. Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998;10(6):548-551.
10. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235-242.
11. Pfreundschuh M, Trümper L, Osterborg A, et al. MabThera International Trial Group. CHOP- like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
12. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184-4190.
13. Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32(31):3490-3496.
14. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. J Clin Oncol. 2017;35(5):544-551.
15. Petersen H, Holdgaard PC, Madsen PH, et al. PET/CT Task Force of the Region of Southern Denmark. FDG PET/CT in cancer: comparison of actual use with literature-based recommendations. Eur J Nucl Med Mol Imaging. 2016;43(4):695-706.
16. Weiler-Sagie M, Bushelev O, Epelbaum R, et al. (18)F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25-30.
20
